The pharma company is waiting for further clarity to assess the impact of tariffs imposed by the Trump administration and the ...

Pharmazz has two late-stage pipeline drug candidates Sovateltide (for treatment of acute cerebral ischemic stroke) and ...

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

Sun Pharmaceutical Industries Ltd. posted a mixed fourth quarter on Thursday and announced a softer-than-expected financial ...

The company also expects R&D spending to rise to 6–8% of sales, reflecting its commitment to pipeline expansion and ...

India’s largest drugmaker plans a $100 million push into US specialty drugs in FY26, even as it braces for regulatory ...

The share price of Sun Pharmaceuticals has fallen by over 4% in the last five trading sessions. The stock has fallen 6% in ...

Sun Pharmaceutical Industries reported a consolidated net profit of ₹2,154 crore in the fourth quarter of FY25, registering a ...

Stock continues to show pressure even with a fine tuned operating performance, US sales decline which skew profit losses.

Sun Pharmaceuticals Industries Ltd has reported a decline of 19 per cent in net profit during the fourth quarter of FY25, ended March 31, 2025 at Rs. 2,149.88 crore as compared to Rs. 2,654.58 crore ...

Planting seed money and “wishing” is not enough to claim “irreparable harm” to secure a preliminary injunction or to establish the standing required to appeal a patent board decision, the U.S. Court ...

The upside is due to a positive ruling by the US court regarding the launch of Leqselvi. The US Court heard arguments in the pharmaceutical company’s appeal against a previous decision by the ...